Highly pro-active pharmaceutical physician (UK GMC registered) with 20 years of relevant clinical and research experience across phases (I to IV) with a special interest in shaping the care environment and transform the treatment experience.Strong “catalizer” in arena development, having developed industrial-academic consortia and several academic and research council collaborations. Experienced in “building up business from scratch”. Participated in the launch of 10 compounds (donanemab, Amyvid, Tauvid, Kyprolis/CANDOR-KdD/carfilzomib, PROLIA/denosumab, EVENITY/romosozumab, ADUHELM/aducanumab, TYSABRI/natalizumab, TECFIDERA/DMF, DELTYBA/delamanid) across 5 TAs (Multiple Myeloma, Osteoporosis, Alzheimer's disease, Multiple Sclerosis, MDR-Tuberculosis). Networker, outgoing, strong negotiation and diplomatic skills, project management, global operations.Experience in Neuroscience (Alzheimer's, Fontotemporal dementia, Parkinson, Huntington, Multiple Sclerosis, Schizophrenia, Depression, Migraine, Muscular Dystrophias), Hemato-oncology (lymphoma, leukemia, multiple myeloma), Endocrinology and Bone Metabolism (Osteoporosis), Infectious Diseases / Neglected Tropical Diseases (Malaria, Tuberculosis, Leishmaniasis, multi-resistant bacteria), Rare Diseases, Neuromuscular diseases (Duchenne, SMA-Spinal Muscle Atrophy, ALS-Amyotrophic Lateral Sclerosis).Strong interest in CAR T-cell therapies, precision medicine, Real World Evidence, gene therapy, epigenetics, Digital Health and Artificial Intelligence in healthcare.